Phase I Evaluation of Intravenous Recombinant Human Interleukin 12 in Patients with Advanced Malignancies1

Abstract

A Phase I dose escalation trial of i.v. administered recombinant human interleuldn 12 (rhIL-12) was performed to determine its toxicity, maximum tolerated dose (MTD), pharmacokinetics, and biological and potential antineoplastic effects. Cohorts of four to six patients with advanced cancer, Karnofsky performance 70%, and normal organ function received… (More)

Topics

8 Figures and Tables